Behandling av hanhundar med deslorelin
This article presents a survey of male dogs treated with the gonadotropin releasing hormone (GnRH) agonist deslorelin (Suprelorin®, Virbac) at three animal clinics in central Sweden. Filled-in questionnaires from 110 dogs were received. The paper also includes a review of existing litterature concer...
| Autor principal: | |
|---|---|
| Formato: | Otro |
| Lenguaje: | sueco sueco |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | https://stud.epsilon.slu.se/11792/ |
| _version_ | 1855571940348002304 |
|---|---|
| author | Jigler, Emilia |
| author_browse | Jigler, Emilia |
| author_facet | Jigler, Emilia |
| author_sort | Jigler, Emilia |
| collection | Epsilon Archive for Student Projects |
| description | This article presents a survey of male dogs treated with the gonadotropin releasing hormone (GnRH) agonist deslorelin (Suprelorin®, Virbac) at three animal clinics in central Sweden. Filled-in questionnaires from 110 dogs were received. The paper also includes a review of existing litterature concerning reproduction in male dogs, focusing on endocrinology, the effects of gonadectomy and the GnRH agonist deslorelin.
Continuous treatment with deslorelin produces infertility in male dogs. The pituitary is
initially stimulated by deslorelin leading to a rise in luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion. As a consequence the testosterone levels also increase temporarily. With long term treatment the receptors of the pituitary get
desensitized, resulting in decreased production of LH, FSH and testosterone with
subsequent suppression of spermatogenesis. The effect remains for at least 6 months.
The purpose of this study is to investigate the causes of treatment and if, when and for how long the dog owners notice any effect of the treatment as well as if any adverse effects are seen. It is also considered whether the initial rise in testosterone levels is apparent for the dog owners and if it is possible for them to observe any change in, for example, behavior or worsening of already existing signs from an enlarged prostate.
It turned out that the most common indications for treatment is different sexual behaviors, aggression and various prostatic disease, mainly benign prostatic hyperplasia. Most of the dog owners tested treatment with deslorelin instead of gonadectomy because they wanted to evaluate the effect of castration on the dog before letting the dog undergo an irreversible surgical procedure. In most of the dogs the owner noticed the effect of treatment within 4 weeks.
In 53 % of the dogs, the owners found that the treatment had had full desired effect and in 16 % there were no desired effect at all. Only occasional dogs showed deterioration of sexual and aggressive behavior during the first month of treatment. None of the dogs treated for prostatic disease showed worsening of prostatic symptoms in the beginning of the treatment, witch indicate that the initial increase in testosterone levels doesn't cause the prostate to grow. Other effects on treated dogs noticed by dog owners were reduced sexual behavior and interest in female dogs, reduced aggression, increased appetite and also that some dogs showed less difficulties to urinate or defecate.
Mean duration of a single treatment with Suprelorin® (Virbac) turned out to be 7,8 months with a variation from 3 to 15 months. |
| format | Otro |
| id | RepoSLU11792 |
| institution | Swedish University of Agricultural Sciences |
| language | Swedish swe |
| publishDate | 2009 |
| publishDateSort | 2009 |
| record_format | eprints |
| spelling | RepoSLU117922017-10-17T07:38:51Z https://stud.epsilon.slu.se/11792/ Behandling av hanhundar med deslorelin Jigler, Emilia Veterinary science and hygiene - General aspects This article presents a survey of male dogs treated with the gonadotropin releasing hormone (GnRH) agonist deslorelin (Suprelorin®, Virbac) at three animal clinics in central Sweden. Filled-in questionnaires from 110 dogs were received. The paper also includes a review of existing litterature concerning reproduction in male dogs, focusing on endocrinology, the effects of gonadectomy and the GnRH agonist deslorelin. Continuous treatment with deslorelin produces infertility in male dogs. The pituitary is initially stimulated by deslorelin leading to a rise in luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion. As a consequence the testosterone levels also increase temporarily. With long term treatment the receptors of the pituitary get desensitized, resulting in decreased production of LH, FSH and testosterone with subsequent suppression of spermatogenesis. The effect remains for at least 6 months. The purpose of this study is to investigate the causes of treatment and if, when and for how long the dog owners notice any effect of the treatment as well as if any adverse effects are seen. It is also considered whether the initial rise in testosterone levels is apparent for the dog owners and if it is possible for them to observe any change in, for example, behavior or worsening of already existing signs from an enlarged prostate. It turned out that the most common indications for treatment is different sexual behaviors, aggression and various prostatic disease, mainly benign prostatic hyperplasia. Most of the dog owners tested treatment with deslorelin instead of gonadectomy because they wanted to evaluate the effect of castration on the dog before letting the dog undergo an irreversible surgical procedure. In most of the dogs the owner noticed the effect of treatment within 4 weeks. In 53 % of the dogs, the owners found that the treatment had had full desired effect and in 16 % there were no desired effect at all. Only occasional dogs showed deterioration of sexual and aggressive behavior during the first month of treatment. None of the dogs treated for prostatic disease showed worsening of prostatic symptoms in the beginning of the treatment, witch indicate that the initial increase in testosterone levels doesn't cause the prostate to grow. Other effects on treated dogs noticed by dog owners were reduced sexual behavior and interest in female dogs, reduced aggression, increased appetite and also that some dogs showed less difficulties to urinate or defecate. Mean duration of a single treatment with Suprelorin® (Virbac) turned out to be 7,8 months with a variation from 3 to 15 months. Det här är en studie som sammanfattar enkätsvar från 110 hanhundar som behandlats med gonadotropin releasing hormone (GnRH)-agonisten deslorelin (Suprelorin®, Virbac) vid tre olika kliniker/djursjukhus i Mellansverige. Uppsatsen innehåller även en litteraturstudie som tar upp hanhundens reproduktionsendokrinologi, vilka effekter gonadektomi har på hanhunden samt GnRH -agonisten deslorelin. Kontinuerlig behandling med deslorelin framkallar infertilitet hos hanhundar. Inledningsvis ses en stimulering av hypofysen så att frisättningen av luteiniserande hormon (LH) och follikelstimulerande hormon (FSH) ökar, vilket leder till en övergående ökad testosteronfrisättning. Men med fortsatt tillförsel av GnRH kommer hypofysens receptorer att desensibiliseras så sekretionen av LH- och FSH samt även testosteron upphör. Eftersom det då heller inte sker någon spermatogenes blir hanhunden infertil under minst 6 månader. I den här studien undersöks orsakerna till att hundarna behandlats med deslorelin samt om, när och hur länge hundägarna såg effekt av behandlingen och ifall några oönskade effekter noterats. Studien utreder även ifall den initiala ökningen av testosteronfrisättningen orsakade någon märkbar förändring på hanhunden t ex i form av ändrat beteende eller tilltagande sjukdomssymtom från en redan förstorad prostata. Det visade sig att de vanligast förekommande indikationerna för behandlingen var översexuellt beteende, aggressivitet och olika former av prostatabesvär, främst benign prostatahyperplasi. Majoriteten av hundägarna hade valt behandling med deslorelin framför gonadektomi eftersom de ville prova vilken effekt en kastration hade på hunden innan ett permanent kirurgiskt ingrepp gjordes. Majoriteten av ägarna såg effekt av behandlingen inom 4 veckor. Hos 53 % av de behandlade hundarna ansåg ägarna att behandlingen haft fullständigt önskad effekt men hos 16 % sågs ingen önskad effekt alls. Endast hos enstaka hundar sågs en ökning av sexuellt- och aggressivt beteende under den första månaden av behandlingen. Ingen av de hundar som behandlades mot prostatabesvär uppgavs få ökade problem i början av behandlingen, vilket tyder på att den ökade testosteronfrisättningen i början inte hinner påverka prostatas storlek. Andra effekter som noterats hos de behandlade hundarna var minskat översexuellt beteende och intresse för tikar, minskad aggressivitet, ökad aptit samt lättare att defekera/urinera. Medeldurationen för behandlingens effekt vid engångsbehandling var 7,8 månader med en variation från 3 till 15 månader. 2009-01-15 Other NonPeerReviewed application/pdf sv https://stud.epsilon.slu.se/11792/1/jigler_e_171017.pdf Jigler, Emilia, 2008. Behandling av hanhundar med deslorelin. UNSPECIFIED, Uppsala. Uppsala: (VH) > Dept. of Clinical Sciences (until 231231) <https://stud.epsilon.slu.se/view/divisions/OID-715.html> urn:nbn:se:slu:epsilon-s-7897 swe |
| spellingShingle | Veterinary science and hygiene - General aspects Jigler, Emilia Behandling av hanhundar med deslorelin |
| title | Behandling av hanhundar med deslorelin |
| title_full | Behandling av hanhundar med deslorelin |
| title_fullStr | Behandling av hanhundar med deslorelin |
| title_full_unstemmed | Behandling av hanhundar med deslorelin |
| title_short | Behandling av hanhundar med deslorelin |
| title_sort | behandling av hanhundar med deslorelin |
| topic | Veterinary science and hygiene - General aspects |
| url | https://stud.epsilon.slu.se/11792/ https://stud.epsilon.slu.se/11792/ |